Slow and steady wins the race… A motto that Nantes-based Ose Immunotherapeutics pharmaceutical group seems to follow as they unveil their candidate vaccine against coronavirus has been delivering encouraging results so far. They announce in a release they have achieved in human ex vivo study, led by CoVepiT, the “prophylactic vaccine against Covid-19”.
A study led in 120 adults recovering from Covid-19 and other people not exposed to the disease that reached its goal, naming initiating the clinical phase “expected to start end of 2020/early 2021”. The French laboratory joined AstraZeneca, Sinovac, Pfizer/BioNTech and even Sanofi and Moderna Therapeutics in the race for a vaccine, but specifically authorized or on-going clinical trials.
What does this candidate vaccine consist in? It is based on optimized epitopes (a molecule than can be recognized by a paratope, a receptor found on the surface of specific antiborides and that can stimulate the production of this antibody) selected to induce a lasting immune response of lymphocytes T, a genuine memory of viruses in the human body, against Covid-19.
A statement accompanied by the presentation of their multi-target and anti-Covid vaccine during the World Immunotherapy Congress held from November 2 to 9, 2020. This is the very first time a second-generation vaccine against coronavirus is presented during a scientific event.
